

JETEMA NEWSLETTER

Contact Us | Global Business Department | global@jetema.com | Tel: +82 70 4337 6932 | www.jetema.com



Strengthening JAMBER's Academic Presence Across China

JETEMA strengthened JAMBER's presence in China throughout the second quarter of 2026 by expanding academic collaboration, clinical education, and local physician engagement across major cities.

The quarter began with a strategic partnership between JETEMA Shanghai and the Korean Society of Aesthetic Medicine (KSAM), establishing a foundation for academic exchange and the development of a local Key Doctor network. Following comprehensive theoretical education and live demonstration training in Korea, selected KSAM members were prepared to lead clinical education and treatment protocol development for JAMBER in China.

Building on this momentum, JETEMA officially launched JAMBER in Hangzhou through a large-scale academic seminar attended by approximately 350 medical professionals, with more than 1,000 additional participants joining via live broadcast. The program showcased JAMBER's clinical value through expert lectures, combination treatment protocols, and live demonstrations.


Subsequent training sessions held in Shenzhen, Shanghai, and Hangzhou further expanded physician education by

providing hands-on training, treatment technique workshops, and the sharing of practical clinical experience. Notably, doctors who completed the Korea-based Key Doctor Training Program have now begun leading educational activities in China, demonstrating the successful localization of JETEMA's academic platform.

Through these initiatives, JETEMA continues to reinforce its long-term commitment to scientific exchange, physician education, and sustainable market growth while strengthening JAMBER's academic presence across China.



KSAM X JETEMA JAMBER Key-Doctor Training Session



JETEMA Launches Renewed Global Website for e.p.t.q.®

JETEMA has launched the renewed global website for its premium HA filler brand, e.p.t.q.®, offering an improved digital platform for global customers and partners. The redesigned website provides a more intuitive user experience while showcasing the brand story, proprietary technologies, product portfolio, and core values through streamlined navigation and refreshed visual content. JETEMA also plans to introduce AI-powered e.p.t.q.® brand models to create diverse digital content and enhance global brand experiences.



e.p.t.q.® Achieves HALAL Certification

e.p.t.q.® has officially received HALAL certification, marking another milestone in its global journey. This certification reinforces JETEMA's commitment to internationally recognized standards of quality, safety, and purity while strengthening trust among customers and partners worldwide. Guided by JETEMA's promise of "Pure Ingredients. Proven Safety. Exceptional Beauty.", e.p.t.q.® will continue to deliver safe, high-quality aesthetic solutions to the global market.

Expanding Global Clinical Education for Ecolla™



JETEMA expanded its global clinical education initiatives through academic programs held in Chile and Portugal during May.

In Chile,

JETEMA officially launched e.p.t.q.® and Ecolla™ through an academic seminar attended by approximately 80 local medical professionals. Clinical lectures highlighted the applications of both products while fostering engagement with the local medical community.

In Portugal,

JETEMA hosted an exclusive "Train the Trainer" seminar introducing advanced body (hip) treatment protocols using e.p.t.q.® S500 3mL and Ecolla™ to Portuguese Key Opinion Leaders (KOLs), further strengthening local clinical expertise ahead of the European expansion of its product portfolio.


Newest Journal Article: Efficacy and safety of e.p.t.q.® hyaluronic acid fillers in the context of aesthetic facial rejuvenation or beautification: a post-market clinical follow-up study

e.p.t.q.® PMCF Study Published in Scientific Reports

A post-market clinical follow-up (PMCF) study on e.p.t.q.® HA fillers has been published in Scientific Reports (Impact Factor 3.9, SCI-indexed), one of the world's most-cited multidisciplinary journals. The prospective, multi-center study followed 231 patients over 24 weeks and found statistically significant improvements ($p = 0.0000$ for all) in nasolabial folds, midface volume, and lip volumization, with zero serious adverse events reported—including in patients aged 70 and older. The findings reinforce the real-world efficacy and safety profile of the e.p.t.q.® portfolio.

Clinically Significant Improvement in All Indications

Nasolabial Folds



Investigator-assessed GAIS
83.3% of patients demonstrated visible improvement at 24 weeks.

Midface Volume



Investigator-assessed GAIS
97.0% of patients demonstrated visible improvement at 24 weeks.

Lip Volume



Investigator-assessed GAIS
93.7% of patients demonstrated visible improvement at 24 weeks.

Ecolla™ Featured in PRIME Journal (May/June 2026)

PRIME PROMOTION

USE OF POLY-L-LACTIC ACID IN ADULT PATIENTS: AESTHETIC APPLICATIONS FOR THE FACE AND BODY

Rocco Carfagna, MD, explains how poly-L-lactic acid continues to evolve beyond traditional volumisation, offering practitioners a regenerative approach to improving skin quality, firmness, and tissue support across both facial and body indications



radiance, and tone. This progressive and natural effect makes PLLA particularly suitable for patients aged 30 to 60, in whom both prevention and correction of skin laxity are complementary objectives.

Mechanism of action

Following intradermal or subcutaneous injection, PLLA

- Volumetric remodelling of the zygomatic region, temples, and jawline
- Correction of lipatrophy (both HIV-related and non-HIV-related)
- Improvement of skin laxity and dermal quality in the cheeks, submental area, and jawline contour
- Preventive treatment of

density and improvement of photodamage¹. The combined effect of neo-collagenesis and dermal thickening gives a smoother and firmer appearance, with gradual and natural results.

Treatment protocol

The protocol varies according to age, patient condition, individual



Before After (90 Days)

Gluteal augmentation case from the article:
before and after three Ecolla™ treatments.

Carfagna R. PRIME Journal, May/June 2026, pp. 38-41.

Feature Overview,

Rocco Carfagna, MD (Salerno, Italy) authored a peer-reviewed feature on poly-L-lactic acid (PLLA) in PRIME Journal, exploring Ecolla™'s regenerative approach to facial and body aesthetics. The article details PLLA's biostimulatory mechanism of action, its main clinical indications, and treatment protocols across different age groups.

Case Series Results,

A clinical case series of 34 patients (aged 26–62) treated with Ecolla™ across facial and body areas demonstrated a favorable safety profile, with no clinically palpable subcutaneous nodules observed, and progressive, natural-looking improvement in skin quality and tissue firmness over time.

Age-Tailored Protocols,

The article outlines an age-based treatment framework: preventive, lower-dose biostimulation for patients aged 30–40; a combined biostimulation and volumetric approach for those aged 40–50; and more structured protocols for patients aged 50–60, often integrated with hyaluronic acid fillers or energy-based devices for optimal results.

JETEMA Activities Worldwide

JAM Training 2026 in U.S.

JETEMA held JAM Training 2026 in the U.S. on April 29, 2026, featuring a headquarters tour, REVAFLUX product introduction, and live demonstrations of REVAFLUX and VITTEN® at ELEV Clinic and Pagelab Clinic for local medical professionals. The event provided an opportunity to enhance product understanding and strengthen JETEMA's brand awareness in the U.S. market.



ASLS TOKYO 2026

JETEMA participated in ASLS TOKYO 2026, hosted by the Korean Aesthetic Surgery & Laser Society (ASLS), where the company operated a dedicated exhibition booth. During the event, Japanese physician Dr. Sato Daiki delivered a lecture on the combined treatment protocol of hADM and Ecolla™ PLLA.



JETEMA Academy 2026 in Bolivia

JETEMA held a JETEMA Academy in Santa Cruz, Bolivia, bringing together approximately 50 local medical professionals for a full-day academic program led by Dr. Kelly Ferraz. The event provided an opportunity to strengthen the branding of JETEMA products and enhance brand awareness in the Latin American market through academic exchange with local physicians.



JETEMA Factory Tour Program

JETEMA welcomed Turkish KOLs to its Yongin factory for its first Medical Device Factory Tour Program. The visit provided a firsthand look at the company's advanced manufacturing facilities and production processes. Participants shared highly positive feedback, noting that the tour reinforced their trust in the safety, quality, and reliability of JETEMA products.

